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Chronic myeloid leukemia (CML) patients in sustained “deep molecular response” may 
stop TKI treatment without disease recurrence; however, half of them lose molecular 
response shortly after TKI withdrawing. Well-defined eligibility criteria to predict a safe 
discontinuation up-front are still missing. Relapse is probably due to residual quies-
cent TKI-resistant leukemic stem cells (LSCs) supposedly transcriptionally low/silent 
and not easily detectable by BCR-ABL1 qRT-PCR. Bone marrow Ph+ CML CD34+/
CD38− LSCs were found to specifically co-express CD26 (dipeptidylpeptidase-IV). 
We explored feasibility of detecting and quantifying CD26+ LSCs by flow cytometry in 
peripheral blood (PB). Over 400 CML patients (at diagnosis and during/after therapy) 
entered this cross-sectional study in which CD26 expression was evaluated by a stan-
dardized multiparametric flow cytometry analysis on PB CD45+/CD34+/CD38− stem 
cell population. All 120 CP-CML patients at diagnosis showed measurable PB CD26+ 
LSCs (median 19.20/μL, range 0.27–698.6). PB CD26+ LSCs were also detectable in 
169/236 (71.6%) CP-CML patients in first-line TKI treatment (median 0.014 cells/μL; 
range 0.0012–0.66) and in 74/112 (66%), additional patients studied on treatment-free 
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remission (TFR) (median 0.015/μL; range 0.006–0.76). Notably, no correlation between 
BCR-ABL/ABLIS ratio and number of residual LSCs was found both in patients on or 
off TKIs. This is the first evidence that “circulating” CML LSCs persist in the majority of 
CML patients in molecular response while on TKI treatment and even after TKI discon-
tinuation. Prospective studies evaluating the dynamics of PB CD26+ LSCs during TKI 
treatment and the role of a “stem cell response” threshold to achieve and maintain TFR 
are ongoing.
Keywords: chronic myeloid leukemia, cD26, leukemic stem cells, TKi, minimal residual disease, flow cytometry
inTrODUcTiOn
For many years since their appearance in the treatment sce-
nario of chronic myeloid leukemia (CML), TKIs have been an 
extraordinary highly effective life-long treatment (1, 2). More 
recently, the demonstration that a fraction of CML patients in 
sustained “deep molecular response” (DMR) may indeed stop 
TKI treatment without recurrence of disease introduced the 
concept of “treatment-free remission” (TFR). Clinical data sug-
gest that treatment duration in addition to deepness of response 
may influence TFR rate and criteria for safe TKI discontinuation 
include a TKI duration >3  years and a MR4 of at least 1  year 
(3–6). However, up to date, it is not possible to predict relapse 
and approximately 40–60% of DMR patients stopping TKIs will 
lose their response and require retreatment (7, 8) while others will 
maintain TFR even with detectable molecular disease in some 
cases (4, 5). Based on available data it is likely that relapse after 
TKI discontinuation may be due to the persistence of leukemic 
stem cells (LSCs) surviving TKIs through the activation of several 
BCR-ABL1-independent pathways (9–11). If this is the scenario, 
qRT-PCR, the most sensitive assay to monitor disease status in 
CML patients, may be inappropriate to quantify residual quies-
cent CML LSCs, which may be transcriptionally low/silent, while 
surviving indefinitely into tumor-specific hypoxic niches (12). 
In the recent past, several authors, including us, have attempted 
to quantify residual LSCs in bone marrow of TKI treated CML 
patients with discordant results mainly due to technical difficul-
ties and relative low numbers of studied patients (13–16).
Based on these premises, the possibility to easily monitor the 
dynamics of CML LSCs during TKI treatment, in terms of rate 
and timing of reduction, could represent an alternative attempt to 
quantify the actual “cellular” residual disease and thus to identify 
optimal candidates for TKI discontinuation in addition to and 
may be even beyond standard molecular response.
Leukemic stem cells supposedly reside within the CD34+/
CD38−/Lin− fraction, which is the same compartment where also 
normal hematopoietic stem cells (HSCs) are found. Different 
biomarkers have been tested to better discriminate the leukemic 
clones from the normal counterpart and recently, Herrmann 
et al. identified CD26 (dipeptidylpeptidase IV) as a potential bio-
marker for the quantification and isolation of CML LSCs in BM 
samples of CML patients (17). In fact, in contrast to other tested 
antigens such as CD90 and IL-1RAP, which are co-expressed on 
CML LSCs, acute myeloid leukemia (AML) LSCs and normal 
HSCs, CD26 was the only marker, expressed in all tested CP CML 
patients, which was not present on CD34+/CD38− SC in normal 
BM or on LSCs of other myeloid neoplasms (17, 18). In this study, 
the authors reported that BM sorted CD26+ LSCs cells were con-
firmed to be BCR-ABL1+ and in short-term colony assays and 
in long-term culture-initiating cells, colony cells derived from 
CD26+ LSCs (obtained from CML patients) contained BCR/
ABL1mRNA, whereas cells of colonies derived from CD26− SC 
(from the same patients) did not contain BCR-ABL1. The 
capability of CD34+/CD38−/CD26+ LSCs fraction to produce a 
myeloid (granulo-monocytic) BCR-ABL1+ engraftment was also 
confirmed by xenotransplantation experiment in NSG mice (17). 
Valent et al. clarified the functional role of CD26 and discovered 
that this cell surface enzyme, when present, can induce degrada-
tion of cytokine ligands such as SDF-1, a molecule that normally 
attracts HSCs and LSCs into the BM niche via CXCR4 receptor 
(19). This degradation facilitates LSCs mobilization from the BM 
niche, suggesting that CD26 could have a fundamental role in 
the regulation of LSCs–niche interaction and help LSCs escape 
TKI treatment. Finally, BM CD26+ LSCs appeared to decrease 
substantially during a successful treatment with TKIs indicating 
that CD26 could also be a good predictive biomarker for moni-
toring CML patients during therapy (20) and that flow cytometry 
approach could be a useful tool for the identification of CML 
LSCs on BM samples by using a CD45+/CD34+/CD38−/CD26+ 
panel as a strict gating strategy (18, 20). Recently, Warfving and 
colleagues revealed a great heterogeneity of BM LSCs through 
the combination of flow cytometry and single-cell molecular 
analysis; however, the crucial role of CD26 antigen was confirmed 
by the evidence that most insensitive TKI cells of the BM LSC 
compartment were defined by a specific Lin−CD34+CD38−/lowCD
45RA−cKIT−CD26+ phenotype (21).
Based on these evidences, considering that routine monitor-
ing of residual LSCs from bone marrow is not practical, the pre-
sent study aims were: (i) to explore the feasibility of CD26+LSC 
flow cytometry evaluation in peripheral blood (PB) in CML 
patients; (ii) to quantify circulating LSCs during TKI treatment 
and during TKI discontinuation, and (iii) to search a correlation, 
if any, between number of residual LSCs and molecular response 
(BCR-ABL/ABL1IS ratio).
PaTienTs anD MeThODs
Patients cohort
Between June 2015 and June 2017, CP CML patients either newly 
diagnosed or during their first-line treatment with any approved 
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TKI, as well as patients in TFR after first line TKI discontinuation 
entered this not interventional cross-sectional study (including a 
total of 468 patients). In addition, a substantial number of patients 
with blood disorders other than CML and normal HSCs donors 
treated with granulocyte-colony stimulating factor (G-CSF) were 
asked to participate to the study as negative control. All subjects 
provided an informed consent in accordance with their institu-
tion policy.
Flow cytometry
Six milliliters of EDTA PB samples (all subjects) and 2  mL of 
EDTA BM samples (only CML patients at diagnosis) were collected 
and centrally analyzed within 24 h at Flow Cytometry lab in Siena. 
Preliminary experiments showed that within 24 h, cell viability 
was superior to 80%. In all PB or BM samples, CD26 expression 
was evaluated by a standardized multiparametric flow cytometry 
analysis on CD45+/CD34+/CD38 population using a four-color 
staining protocol with lyse stain wash procedure. Briefly, red cell 
lysis was performed with ammonium chloride (BD Biosciences), 
1:10 diluted in deionized water, using Lyse Wash Assistant instru-
ment (BD Biosciences). After lysis, 2.0 ×  106 leukocytes were 
incubated with a custom made lyophilized pre-titrated antibody 
mixture test tube (BD™ Lyotubes, BD) including CD45 V500 
(BD Pharmingen clone 2D1), CD34 FITC (BD Pharmingen 
clone 581), CD38 APC (BD Pharmingen clone HIT2), and CD26 
PE (BD Pharmingen clone M-A261) antibodies and a BD stain 
control tube lacking the CD26. To reach a sensitivity of 10−5, 
acquisition and analysis of at least 1.0 × 106 cells was performed 
in all samples by FACSCanto II flow cytometer using a DIVA 8 
software (BD, Biosciences). Additionally, to ensure reproducible 
results over time, we followed a standardized protocol that implied 
adjustments of FACS internal parameters, using the CS&T System 
(BD Biosciences), to keep constant the instrument performance 
by correcting wear of lasers and fluidic instability (22). Figure 1 
Panel A, a–e shows step by step CD26+LSC flow cytometry analy-
sis of one representative CML PB sample at diagnosis.
In a smaller cohort of patients, the co-expression of CD90 
PeCy7 (BD Pharmingen clone 5E10) was tested to further con-
firm that CD45+CD34+CD38−CD26+ population belongs to the 
stem cell compartment (Figure 1 Panel A, f).
Quantitative rT-Pcr
Simultaneously to CD26+ LSCs measurement CML patients 
were evaluated for PB BCR-ABL1 transcript levels by standard 
qRT-PCR analysis, according to European Leukemia Net (ELN) 
criteria (1). All blood samples were tested within the Italian 
molecular laboratory net for CML (Labnet CML) under strin-
gent quality control testing. Undetectable level of BCR-ABL1 is 
referred as 0 mRNA copies detected in 32,000 ABL copies (MR4.5) 
or in 100,000 ABL copies (MR5).
statistical analysis
To estimate putative differences in the levels of each single bio-
chemical variable, we employed the Mann–Whitney U-test and 
the Wilcoxon test for comparisons between and within groups 
if applicable. The Kendall rank correlation coefficient was used 
to detect putative relations among the measurable variables. 
Furthermore, the Mood test and bi-linear relation modeling were 
employed to evaluate the putative relations among parametric 
and the nonparametric data such as standard MR categories. 
p < 0.05 was accepted as statistically significant. All calculations 
were performed using the SPSS library version 13 (SPSS Inc. 
Chicago, IL, USA).
resUlTs
cD26+ lscs evaluation at Diagnosis
During study time frame, 120 newly diagnosed CML patients 
were tested for circulating PB CD26+LSCs. In 80/120 (67%), the 
analysis was performed simultaneously also in BM samples. All 
PB and BM samples of CP-CML patients scored positive for the 
presence of CD26 LSCs (120/120, 100%). In particular, within 
the CD34+/CD38− stem cell fraction, the median percentage 
of CD26+ cells was 21% (range 0.56–77.16) and 36.9% (range 
4.2–98.8) in BM and PB samples, respectively. However, the 
median absolute number of CD26+ cells/μL [calculated as fol-
low: (no. WBCs/μL) ×  (% of CD34+/CD38−/CD26+ on CD45+ 
cells)] was comparable in BM and PB samples: 18.38/μL (range 
0.063–309.12) and 19.20/μL (range 0.27–698.6), respectively. 
This concordance of results allowed us to quantify LSCs directly 
from PB samples. Figure 1 Panel A, a–e shows CD26+LSC flow 
cytometry analysis of one representative CML PB sample at 
diagnosis. Of note, in CML PB samples, at diagnosis, the number 
of CD26+ LSCs correlated with the total WBC count (p < 0.01).
cD26+ lscs evaluation During  
TKi Treatment
Peripheral blood samples of 236 CP CML patients on first-
line treatment with any approved TKI were also evaluated for 
circulating CD26+ LSCs during a routinely molecular response 
assessment according to ELN guidelines. Type of TKI, treatment 
length, molecular response, and quantification of circulating 
LSCs are summarized in Table  1. PB CD26+ LSCs were detect-
able in 169/236 (71.6%) patients with a median number of 0.014 
CD26+cells/μL (range 0.0012–0.66). Figure 1 Panel B, a,b shows 
PB CD26+LSC evaluation in a representative CML patient on 
TKI treatment (imatinib) for 29  months. PB BCR-ABL/ABLIS 
ratio in these 169 samples with measurable CD26+ LSCs showed 
a median value of 0.007% (range 0–61). Kendall rank correlation 
coefficient used to analyze the relationship between the variables 
showed no correlation between BCR-ABL/ABLIS ratio and num-
ber of residual CD26+ LSCs (r = 0.118 p = 0.097). Even when we 
compared measurable CD26+ LSCs and BCR-ABL log reduction 
(expressed in standard MR categories, i.e., MR1, MR2, MR3, MR4, 
MR4.5) according to the Mood test and bi-linear relation model, 
no significant correlation was found (U = −0.105, p = 0.091). In 
67/236 (28.4%) patients, PB CD26+ LSCs were undetectable; in 
this sub-group, a specific analysis by the Kendall rank correlation 
coefficient found no correlation with the concomitant degree of 
molecular response (r = 0.14, p = 0.097). Similarly, in 45/236 (19%) 
patients with undetectable BCR-ABL1/ABL1IS and 191/236 (81%) 
with detectable BCR-ABL1/ABL1IS, no correlation was found with 
the number of residual PB CD26+ LSCs [Kendall rank correlation 
FigUre 1 | Continued
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coefficient: r = 0.019 (p = 0.09) and r = 0.157 (p = 0.094)] (Table 1). 
Finally, no correlation between BCR-ABL1/ABL1IS and number of 
PB CD26+ LSCs was shown even considering the whole cohort of 
236 patients (r = 0.101, p = 0.112).
cD26+ lscs evaluation During TFr
A total of 112 CP CML patients in TFR for a median of 31 months 
(range 1–152) were evaluated. All 112 patients were in first line 
treatment at the time of TKI withdrawal. Sixty-eight out of 112 
TaBle 2 | Peripheral blood CD26+ leukemic stem cells (LSCs) evaluation in chronic myeloid leukemia patients during treatment-free remission.
Total pts iMaTiniB treated pts nilOTiniB treated pts DasaTiniB treated pts
No. 112 68 28 16
Median treatment-free remission time (range) 31 (1–152) 38 (3–152) 19 (1–78) 32 (9–90)
No. pts with detectable CD26+ LSCs (%) 74/112 (66.1%) 49/68 (72%) 17/28 (61%) 9/16 (56%)
Median no. CD26+LSCs/μL (range) 0.015/μL (0.006–0.76) 0.02/μL (0.006–0.76) 0.016/μL (0.007–0.67) 0.016/μL (0.007–0.47)
TaBle 1 | Peripheral blood CD26+ leukemic stem cells (LSCs) evaluation in chronic myeloid leukemia (CML) patients during TKI treatment.
Total pts iMaTiniB treated pts nilOTinB treated pts DasaTiniB treated pts
No. 236 108 90 38
Median TKI treatment duration (months) 36 (1–195) 68 (2–195) 24 (1–132) 12 (2–133)
CML patients with detectable peripheral blood (PB) CD26+ 
LSCs (%)f
169/236 (71.6%) 77/108 (71.2%) 65/90 (72.2%) 27/38 (68.4%)
Median 0.007 (0–61) 0.006 (0–61) 0.01 (0–8.1) 0.014 (0–0.35)
BCR-ABL1ISratio (range)a
Median 0.014 (0.0012–0.66) 0.014 (0.0029–0.24) 0.019 (0.0012–0.66) 0.0099 (0.0018–0.09)
No. CD26+ LSCs/μL (range)a
CML patients with undetectable PB CD26+ LSCs (%) 67/236 (28.4%) 31/108 (28.8%) 25/90 (27.8%) 11/38 (31.6%)
Median 0.005 (0–0.74) 0.002 (0–0.74) 0.006 (0–0.68) 0.099 (0.002–0.39)
BCR-ABL1ISratio (range)b
CML patients with undetectable BCR-ABL1ISc 45/236 (19%) 25/108 (23.1%) 17/90 (18.8%) 3/38 (8%)
Median no. CD26+ LSCs/μL (range)d 0.0102 (0–0.0744) 0.0058 (0–0.0346) 0.022 (0–0.0744) 0.0185 (0.0133–0.0237)
CML patients with detectable BCR-ABL1IS 191/236 (81%) 83/108 (76.9%) 73/90 (81.2%) 35/38 (92%)
Median no. CD26+ LSCs/μL (range)e 0.0079 (0–0.66) 0.0088 (0–0.24) 0.00815 (0–0.66) 0.0018 (0–0.29)
aKendall rank correlation coefficient: r = 0.118 (p = 0.097).
bKendall rank correlation coefficient: r = 0.14 (p = 0.097).
cPatients with undetectable BCR-ABL1 in a sample with a calculated detection limit of ≥4.5 logs below standardized baseline.
dKendall rank correlation coefficient: r = 0.019 (p = 0.091).
eKendall rank correlation coefficient: r = 0.157 (p = 0.094).
fEven when we compared detectable PB CD26+ LSCs and BCR-ABL log reduction (expressed in standard MR categories, i.e., MR1, MR2, MR3, MR4, MR4.5) according to the Mood 
test and bi-linear relation model, no significant correlation was found (U = −0.105, p = 0.091).
FigUre 1 | Peripheral blood (PB) CD26+ leukemic stem cells (LSCs) flow cytometry evaluation in chronic myeloid leukemia (CML) patients at diagnosis, during TKI 
treatment and during treatment-free remission. (Panel a) PB CD26+ LSC evaluation in a representative CML patient at diagnosis. CD34+CD38−CD26+ cells were 
identified using sequential gate with the aim to exclude debris and doublets. First, CD34 gate was performed only on viable cells identified by FSC and SSC light 
properties (a); then, exclusively CD34+CD38− population was gated (b). Both CD34+ and CD34+CD38− populations show CD45dim expression (c). Negative control 
(d); CD26 expression on CD34+CD38− population (e), and CD90 co-expression on CD34+CD38−CD26+ cell (f). In the case here depicted, the percentage of CD26+ 
cells within the CD34+CD38− fraction was 93%. (Panel B) PB CD26+ LSC evaluation in a representative CML patient during TKI treatment. Circulating CML LSCs 
were documented in about 70% CML patients on treatment regardless of type of TKI, length of treatment, and molecular response. This flow cytometry panel shows 
the presence of PB residual CD26+ LSCs in a CML patient on imatinib for 29 months. In this case, the percentage of CD26+ cells within the CD34+CD38− fraction 
was 8% corresponding to 0.131/μL of circulating CD26+ LSCs. (a) control tube; (b) test tube CD26 expression; (c) co-expression of CD90 on CD26+LSCs. 
(Panel c) PB CD26+ LSC evaluation in a representative patient during treatment free remission (TFR). This flow cytometry panel shows the presence of PB residual 
CD26+ LSCs in a CML patient during TFR. In this case, the percentage of CD26+ cells within the CD34+CD38− fraction was 1.2% corresponding to 0.0054/μL of 
circulating CD26+ LSCs. (a) control tube; (b) test tube CD26 expression; (c) co-expression of CD90 on CD26+LSCs.
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(61%) patients discontinued imatinib treatment and were in TFR 
for a median of 38 months (range 3–152); 28/112 (25%) patients 
discontinued nilotinib and were in TFR for a median 19 months 
(range 1–78) and 16/112 (14%) patients were in TFR for a median 
of 32 months (range 9–90) after dasatinib treatment (Table 2).
When considering the whole cohort of TFR patients, PB 
CD26+ CML LSCs were measurable in 74/112 (66%) patients 
with a median number of 0.015/μL (range 0.006–0.76). Table 2 
shows CD26+ LSCs evaluation in the whole cohort and according 
to previous TKI treatment: persistence of circulating CD26+ LSCs 
was found in 72, 61, and 56% of imatinib, nilotinib, and dasatinib 
treated patients, respectively (p = 0.069 among groups).
Regarding molecular response, only 41/112 (36%) patients 
showed detectable BCR-ABL1 copies (median BCR-ABL1/ABLIS 
ratio 0.0062 range 0.0032–0.493). Indeed, 33/112 (29%) patients 
showed both circulating CD26+ LSCs and detectable BCR-ABL1, 
29/112 (26%) patients scored negative for both determinations, 
while 42/112 (38%) patients showed detectable CD26+ LSCs 
and undetectable BCR-ABL1. Only 8/112 (7%) patients showed 
measurable BCR-ABL1 copies and undetectable CD26+ LSCs 
FigUre 2 | Peripheral blood CD26+ leukemic stem cells and BCR-ABL1IS transcript in the whole cohort of treatment-free remission patients. BCR-ABL1IS 
neg = undetectable BCR-ABL1 transcript [no BCR-ABL1 copies/32,000 ABL copies (MR4.5) or no BCR-ABL1 copies/100,000 ABL copies (MR5)].
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(Figure 2). Kendall rank correlation coefficient, Mood test and 
bi-linear relation model of the whole cohort showed no correla-
tion between BCR-ABL1/ABLIS ratio and number of residual 
LSCs, while a significant linear inverse correlation was found 
between number of circulating CD26+ LSCs and TFR duration 
(r = −0.050 e p = 0.0107).
Validation of results
PB CD26+ LSCs Are Philadelphia-Positive
To validate CML specificity of PB CD26+ LSCs detected during 
TKI treatment and to confirm that also circulating CD26+ LSCs 
are Philadelphia-positive, we performed dual fusion BCR-ABL1 
FISH analysis of PB sorted CD34+/CD38−/CD26+ in five CML 
patients at 3–6 months after starting TKI treatment. A median 
of 10 cells (range 5–13) were detected in CD34+/CD38−/CD26+ 
fraction, and all cells were found BCR-ABL1 positive, confirming 
the results previously reported in BM experiments (17). To further 
confirm CML specificity of PB CD26+ LSCs flow cytometry assess-
ment, we tested for the presence of CD45+/CD34+/CD38−/CD26+ 
cells a consistent number of PB samples from patients affected 
by other blood disorders, such as idiopathic myelofibrosis (IMF) 
(12 samples) Ph+  acute lymphoblastic leukemia (Ph+  ALL, 5 
samples) AML (10 samples). In addition, nine PB samples from 
healthy donors undergoing HSCs mobilization after G-CSF were 
evaluated as well. Despite the presence of variable amounts of 
circulating CD45+/CD34+/CD38− stem cells, in none of these PB 
samples studied a co-expression of CD26 was recorded [Figure 3 
shows the absence of circulating CD26+ LSCs in a representative 
IMF patient (a, b), Ph+ ALL patient (c, d), AML patient (e, f), and 
healthy donor (g, h), respectively].
CD34+/CD38−/CD26+ Population Belongs  
to the Stem Cell Compartment
To confirm that CD34+/CD38−/CD26+ cells are indeed true “stem 
cells,” the concomitant expression of CD90 antigen was also 
evaluated. We tested PB and BM samples of 32 newly diagnosed 
CML patients and, in all of them, CD26+ LSCs fraction showed 
co-expression of CD90. Figure 1 shows CD26+ LSCs expressing 
CD90 in a representative patient at diagnosis (Figure 1 Panel A, e). 
The co-expression of CD90 was retained also in residual circulating 
CD26+ LSCs during TKI treatment (Figure 1 Panel B, c) and after 
TKI discontinuation (Figure 1 Panel C, c).
DiscUssiOn
This study represents the first attempt to measure, in a large 
cohort of CP CML patients, blood circulating LSCs at diagnosis, 
during TKI treatment and even during TFR, a condition that 
represent the actual best surrogate for “cure” in CML patients. In 
our hands, PB CD26+LSC flow cytometry assay appeared feasible, 
reproducible, specific, and sensitive and thus suitable for routine 
monitoring.
First, we clearly demonstrated that 100% of CML patients at 
diagnosis show CML-specific CD26+ LSCs and that CD26+ LSCs 
absolute number is superimposable in PB and BM samples allow-
ing us to easily quantify LSCs directly in PB.
Second, as somehow expected, we found that the majority of 
CML patients undergoing any of approved first line TKI treatment 
still harbored measurable residual LSCs, even when displaying a 
consistent DMR. No correlation with type of TKI and persistence 
of circulating LSCs was found. Surprisingly, the absolute number 
of PB CD26+ LSCs did not correlate with the molecular response 
expressed as BCR-ABL1IS ratio or as MR categories and most of 
patients with undetectable BCR-ABL1 transcript, still showed cir-
culating CD26+LSCs. These data support the evidence that qRT-
PCR accurately measures transcript level but cannot as precisely 
estimate the actual CML cell number. Additionally, our results 
suggest that molecular response mainly refers to transcription-
ally active CML progenitor cells while quiescent, TKI-resistant, 
CML LSCs may be transcriptionally low/silent and thus much less 
detectable by qRT-PCR. The evidence that in our study about 30% 
of CML patients on TKI treatment do not show detectable CD26+ 
LSCs by flow cytometry may be due to the sensitivity of the assay 
but may also reflect a real exhaustion of LSCs.
FigUre 3 | Representative histograms of the expression of isotype control and CD26 on CD34+CD38− fraction in peripheral blood (PB) of normal subjects and 
patients affected by other blood disorders. (a) Negative control, (B) CD26 in a representative case of idiopathic myelofibrosis, (c) negative control,  
(D) CD26 in a representative case of a Ph+ acute lymphoblastic leukemia, (e) negative control, (F) CD26 in a representative case of acute myeloid leukemia,  
(g) negative control, (h) CD26 in a representative normal donor after receiving G-CSF.
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The third important message of our study is that, yet not 
unexpectedly, we have found residual circulating CD26+LSC 
also in 66% of CML patients studied while in prolonged and 
stable TFR. No statistically significant correlation was found 
between previous TKI treatment and persistence of PB LSCs 
even though we registered a higher percentage of patients with 
residual CD26+ LSCs in the subgroup in TFR after discontinuing 
imatinib. Again, no clear correlation was found between abso-
lute number of circulating LSCs and the degree of molecular 
response (expressed in BCR-ABL1/ABLIS ratio) and it is note-
worthy that in 38% of patients with “undetectable” BCR-ABL1, 
we could still measure circulating CD26+ LSCs while only 7% of 
patients scored negative for PB LSCs while showing a detectable 
BCR-ABL1 transcript. When considering the whole cohort of 
112 TFR patients, we found an inverse correlation between PB 
CD26+ LSCs number and TFR duration albeit this observation 
still needs to be validated in a larger series of patients. However, 
the confirmation that most TFR patients still carry quiescent 
CML stem cells (molecularly “silent?”) aligns with clinical 
observation that other factors, likely including a CML-specific 
immune response, may contribute to CML LSCs control and 
avoid disease recurrence after TKI discontinuation.
Our data, including a total of 348 patients, furnish for the 
first time a robust evidence that circulating CML LSCs persist 
in the majority of CML patients while on TKI treatment or after 
TKI discontinuation. The clinical value of monitoring residual 
CD26+ LSCs in addition to standard molecular response still 
needs to be validated; however, our data reinforce the concept 
that measurement of BCR-ABL1 transcript only may not reflect 
the actual residual CML LSCs burden. The possibility to easily 
detect and quantify by flow cytometry PB CML LSCs may open 
new challenges in CML research and rises novel questions. The 
number of circulating CD26+ LSCs at diagnosis and the slope of 
their reduction may play a role in achieving an optimal response 
and subsequently a successful TFR? Is there a LSCs “threshold” 
that keeps patients from CML relapse? Is CD26+ LSCs the target 
of immune system for disease control? To answer some of these 
questions, prospective studies evaluating in newly diagnosed CP 
CML patients, the dynamics of PB CD26+ LSCs during different 
TKI treatment, as well as studies monitoring PB CD26+ LSCs 
prospectively in CML patients that discontinued TKIs, are cur-
rently ongoing.
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